热门资讯> 正文
比较 VistaGen Therapeutics（纳斯达克股票代码：VTGN）和帕拉泰克制药（纳斯达克股票代码：PRTK）
2023-03-14 15:59
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) and VistaGen Therapeutics (NASDAQ:VTGN – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Insider and Institutional Ownership
41.9% of Paratek Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.3% of VistaGen Therapeutics shares are owned by institutional investors. 8.0% of Paratek Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Get Paratek Pharmaceuticals alerts:Volatility & Risk
Paratek Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
Profitability
This table compares Paratek Pharmaceuticals and VistaGen Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Paratek Pharmaceuticals | -76.10% | N/A | -52.54% |
| VistaGen Therapeutics | -5,614.37% | -158.24% | -125.05% |
Earnings and Valuation
This table compares Paratek Pharmaceuticals and VistaGen Therapeutics' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Paratek Pharmaceuticals | $130.16 million | 0.75 | -$59.08 million | ($1.70) | -1.04 |
| VistaGen Therapeutics | -$364,000.00 | -90.56 | -$47.76 million | ($0.31) | -0.48 |
VistaGen Therapeutics has lower revenue, but higher earnings than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Paratek Pharmaceuticals and VistaGen Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Paratek Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| VistaGen Therapeutics | 0 | 4 | 0 | 0 | 2.00 |
Paratek Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 1,036.36%. Given Paratek Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Paratek Pharmaceuticals is more favorable than VistaGen Therapeutics.
Summary
Paratek Pharmaceuticals beats VistaGen Therapeutics on 11 of the 14 factors compared between the two stocks.
About Paratek Pharmaceuticals
(Get Rating)
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
About VistaGen Therapeutics
(Get Rating)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
